This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Carol Karp Biography and Net Worth

Insider of Prothena

Ms. Karp has served as our Chief Regulatory Officer since 2016. Prior to joining Prothena, she was an independent regulatory consultant to biotechnology and pharmaceutical companies. From 2013 to 2014, she was Senior Vice President, Regulatory Affairs and Compliance at Esperion Therapeutics, and from 2010-2013 she held several positions at Janssen Alzheimer Immunotherapy, a Johnson & Johnson company, including Vice President, Head of Global Regulatory Affairs, Pharmacovigilence & Risk Management, where she led global regulatory affairs, regulatory operations and CMC regulatory for a portfolio of neurodegenerative disease product candidates. Ms. Karp was Senior Vice President, Regulatory Affairs, QA and Drug Safety at CV Therapeutics, which was acquired by Gilead Sciences, and has held senior regulatory and scientific affairs positions at PowderJect, VIVUS, Cygnus and Janssen Pharmaceuticals. Ms. Karp is a member of the Board of Trustees for the University of Rochester, and an expert advisor and member of the selection and review committees for the Stanford University School of Medicine’s SPARK translational research program. Ms. Karp earned her BA in biology from the University of Rochester.

How old is Carol D. Karp?: Ms. Karp is currently 71 years old. There are 7 older executives and no younger executives at Prothena. Learn More on Carol D. Karp's age.
How do I contact Carol D. Karp?: The corporate mailing address for Ms. Karp and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Carol D. Karp's contact information.
Has Carol D. Karp been buying or selling shares of Prothena?: Carol D. Karp has not been actively trading shares of Prothena within the last three months. Most recently, Carol D. Karp sold 5,000 shares of the business's stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $46.62, for a transaction totalling $233,100.00. Learn More on Carol D. Karp's trading history.
Who are Prothena's active insiders?: Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.
Are insiders buying or selling shares of Prothena?: During the last twelve months, insiders at the biotechnology company sold shares 33 times. They sold a total of 307,333 shares worth more than $20,322,452.52. The most recent insider tranaction occured on January, 24th when CAO Karin L. Walker sold 5,000 shares worth more than $170,000.00. Insiders at Prothena own 28.1% of the company. Learn More about insider trades at Prothena.
Information on this page was last updated on 1/24/2024.

Carol D. Karp Insider Trading History at Prothena

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
10/4/2023	Sell	5,000	$46.62	$233,100.00
9/6/2023	Sell	5,000	$54.76	$273,800.00
7/5/2023	Sell	5,000	$68.13	$340,650.00
11/1/2021	Sell	10,000	$57.18	$571,800.00
10/1/2021	Sell	10,000	$68.23	$682,300.00

Carol D. Karp Buying and Selling Activity at Prothena

Prothena Company Overview

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $21.29

$20.87

$21.79

50 Day Range

MA: $25.78

$20.57

$30.30

2 Week Range

Now: $21.29

$20.42

$79.65

Volume

356,639 shs

Average Volume

531,677 shs

Market Capitalization

$1.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.21